<DOC>
	<DOCNO>NCT01768013</DOCNO>
	<brief_summary>The pharmacokinetics LEO 90105 ( calcipotriol hydrate plus betamethasone dipropionate ) Japanese subject extensive psoriasis vulgaris .</brief_summary>
	<brief_title>The Pharmacokinetics LEO 90105 ( Calcipotriol Hydrate Plus Betamethasone Dipropionate ) Japanese Subjects With Extensive Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Japanese subject understood sign write informed consent form prior study related procedure carry ( include activity related wash period ) 20 year age . Either sex . Clinical diagnosis psoriasis vulgaris amenable topical treatment involve arm and/or trunk and/or leg . Psoriasis vulgaris trunk/limbs ( exclude psoriasis genitals/skin fold ) 30 % body surface area ( BSA ) An Investigator 's global assessment disease severity ( IGA ) area ( ) treat moderate , severe severe mPASI score â‰¥12 . Females childbearing potential must negative result urine pregnancy test Day 1 ( Visit 1 ) must agree use adequate method birth control , judge ( sub ) investigator , study . The contraceptive method start adequate amount time pregnancy test , dependent particular method use judge ( sub ) investigator , must continue least 1 week last application study medication . A female defined childbearing potential postmenopausal ( 12 month menses without alternative medical cause ) surgically sterile ( tubal ligation /section , hysterectomy bilateral ovariectomy ) . Systemic use biological treatment potential effect psoriasis vulgaris within follow time period prior Visit 1 : etanercept , adalimumab , infliximab 3 month . ustekinumab 4 month product within 3 months/5 halflives ( whichever longer ) . Systemic treatment therapy biological treatment potential effect psoriasis vulgaris ( e.g. , corticosteroid , vitamin D analogue , retinoids , immunosuppressant ciclosporin methotrexate ) within 4 week prior Visit 1 ( use inhale nasal corticosteroid allow , use systemic antihistamine allow ) . Topical treatment scalp psoriasis vitamin D analogue ( e.g . calcipotriol , tacalcitol , maxacalcitol ) , potent WHO group IV corticosteroid within 2 week prior Visit 1 . PUVA therapy , UVB therapy UVA therapy within 4 week prior Visit 1 . Topical treatment psoriasis face , genitals skin fold vitamin D analogue ( e.g . calcipotriol , tacalcitol , maxacalcitol ) , potent potent WHO group III IV corticosteroid within 2 week prior Visit 1 . Topical treatment psoriasis area ( ) treat study medication within 2week period prior Visit 1 . ( Use emollient allow 2 week period , study . ) Planned initiation , change , concomitant medication may affect psoriasis vulgaris ( e.g. , betablockers , antimalaria drug , lithium ACE inhibitor ) study . Topical treatment condition psoriasis vitamin D analogue ( e.g . calcipotriol , tacalcitol , maxacalcitol ) , potent potent WHO group III IV corticosteroid within 2 week prior Visit 1 . Current diagnosis erythrodermic , exfoliative , guttate pustular psoriasis . Clinical sign symptoms Cushing 's disease Addison 's disease Patients follow disorder ( ) symptom ( b ) present area ( ) treat study medication : ( ) viral ( e.g. , herpes varicella ) lesion skin , fungal bacterial skin infection , parasitic infection , skin manifestation relation syphilis tuberculosis , rosacea , acne vulgaris , atrophic skin , stria atrophicae , ichthyosis , acne rosacea , ulcer , burn , frostbite , wound , ( b ) fragility skin vein . Other inflammatory skin disease ( e.g. , seborrhoeic dermatitis , contact dermatitis cutaneous mycosis ) may confound evaluation psoriasis vulgaris . Planned excessive exposure treat area ( ) either natural artificial sunlight ( include tan boths , sun lamp , etc ) study . Known suspect disorder calcium metabolism associate hypercalcaemia ( subject result albumincorrected serum calcium reference range sample take Washout/Screening Visit . Severe renal insufficiency , severe hepatic disorder severe heart disease . Known suspected hypersensitivity component investigational product . Current participation interventional clinical study Subjects receive treatment nonmarketed drug substance ( i.e . agent yet make available clinical use follow registration ) within 4week period prior Visit 1 long , class substance require long washout define ( e.g . biological treatment ) . Females pregnant , wish become pregnant study , breastfeed Patients suspect unable comply study protocol , e.g . due alcoholism , drug dependence psychotic state . Previous enrollment study . Hospitalised patient .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>